Opinions expressed in articles and other materials are those of the authors; they do not necessarily reflect IMF policy. SOURCES: Coursera. 2023. “Artificial Intelligence (AI) Terms: A to Z Glossary.” ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, Lexicon Pharmaceuticals (NASDAQ:LXRX) ...
Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...
Lexicon Pharmaceuticals Inc. (LXRX) reported its third-quarter 2025 earnings, showcasing a notable improvement in both revenue and earnings per share (EPS) compared to analyst expectations. The ...
THE WOODLANDS, Texas - Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a $523 million market cap biotech company with a strong liquidity position, is moving forward with the 10 mg dose of its ...
THE WOODLANDS, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced an update to the previous submission of additional clinical data to the U.S. Food ...
(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, ...
The City of Rison has announced that their water system will be shutting down at 10 p.m. on Wednesday, Jan. 14. Heber Springs man sentenced to 15 years for attempted child pornography distribution A ...
March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can lead to ...
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback